Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 06 Dec 2016 Trial design presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 02 Dec 2016 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
- 02 Dec 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Nov 2018.